NDH.com

icon


Wolters Kluwer | Lippincott Williams & Wilkins
Drug Warnings
orange bar


   Web Toolkit

   Drug Updates

   Patient Teaching

   News Capsules

   Drug Warnings

   Herbal Spotlight

   Drug Info and
   Nursing Links


   CE Tests

   Career Opportunities

   Drug Info Bookstore

   Feedback

   Registration

   Disclaimer



immunosuppressant drugs
Various trade names for immunosuppressant drugs
  Pharmaceutical company:
Various manufacturers

NEW WARNING
The Food and Drug Administration (FDA) is requiring manufacturers of the immunosuppressant drugs sirolimus (Rapamune), cyclosporine (Sandimmune), cyclosporine modified (Neoral), mycophenolate mofetil (CellCept), mycophenolic acid (Myfortic), and their generics to update labeling information to warn of the increased risk of opportunistic infection in immunosuppressed patients. After analyzing its Adverse Event Reporting System, the FDA noted an increased risk of the activation of latent viral infections, including BK virus–associated nephropathy, which is primarily seen in renal transplant patients. BK virus–associated nephropathy can lead to renal allograft loss. Health care providers should monitor patients closely and adjust therapy immediately if BK virus–associated nephropathy develops. Immunosuppressant drugs are indicated to protect against rejection after organ transplantation.

     
   

Home - Guest Registry - Customer Service

Brought to you by Lippincott Williams & Wilkins.
For help on how you should use this site, see our
Disclaimer .

© Copyright 2010 by Lippincott Williams & Wilkins